Show Notes
Based in Mississauga, Ontario, Kare Chemical Technologies is a synthetic chemistry company working on something that sounds unlikely but could change how we treat chronic pain. By converting a byproduct of citrus orange peels into pharmaceutical grade cannabinoids, the company is developing non-psychoactive alternatives to opioids for patients dealing with long-term pain. In this episode, host Jim Wilson speaks with co-founder and COO Kareem Abdur-Rashid about a company that began with a family member's diagnosis, a father's decades of experience in organometallic chemistry, and a young scientist who signed up before fully realizing what he was getting into. Kareem walks through how the technology works, how the company bootstrapped its way to its first licensee, and why chronic pain remains one of the most underfunded areas in pharmaceutical development. This conversation is a candid look at early stage entrepreneurship from someone who is still in the thick of it, learning as he goes and building something that could genuinely help people get their lives back. We thank the NRC for supporting the NGBi podcasts. The National Research Council of Canada (NRC) is the Government of Canada's largest federal research and technology organization, focused on accelerating innovation, research, and development.
More from NGBi Podcasts
Allison Brown is the site head of BioLabs University of Toronto, the first Canadian location in a global network of shared lab and office facilities spanning twenty biotech innovation clusters around the world. Located in the MaRS Discovery District, it puts her at the epicentre of innovation and commercialization in Canadian life sciences.
Andrea Ladouceur is President and CEO of the Biosciences Association of Manitoba, or BAM, a not-for-profit industry association based in Winnipeg that is focused on growing the province's life sciences sector.
Trigger warning: This episode touches on themes of mental health and loss of life. Listener discretion is advised. Neil Fraser is one of the most respected leaders in Canada's medtech sector. He spent 38 years at Medtronic Canada, serving as president from 2004 to 2022, and has been a longtime advisor on health innovation policy and a director on numerous boards.
Greg Wolfond is the founder of the Give Back Health Innovation Foundation, a Canadian philanthropic network working to advance public health through innovation and technology. It tackles one of the most persistent problems in Canadian life sciences: the country does world-class research yet ranks near the bottom when it comes to commercializing it.
Dr. Michael Rudnicki is co-founder and Chief Discovery Officer of Satellos Bioscience in Ottawa, and one of the most accomplished stem cell scientists in the world. A member of the Order of Canada and a Fellow of the Royal Society of London, his work sits at the leading edge of regenerative medicine. In this episode, host Jim Wilson speaks with Michael about a life shaped by science, family, and curiosity, from taking apart the family car as a kid in Ottawa to building some of the first knockout mice at MIT's Whitehead Institute. Michael reflects on the mentors and moments that shaped his path, the founding of Canada's Stem Cell Network, and the discoveries in his lab that led to Satellos. At the heart of the conversation is the company's mission: a paradigm-shifting approach to Duchenne muscular dystrophy that treats the disease as a stem cell signaling problem rather than simply a structural one, and the hope that it could change the lives of patients living with this devastating condition.